⁦Congratulations to james mckiernan⁩ being honored tonight ⁦fans4thecure⁩ ALL-STAR Celebration Dinner for all his contributions for the management of Urological Cancers

Great article about BCG shortage with Alexander Kutikov MD my bbf (🧐) Scott Gottlieb, MD 🇺🇸

Only TWO WEEKS until our premier #BladderCancer advocacy and scientific meeting, Think Tank 2019 #BCANTT2019. Who's going?

An extraordinary story of a patient’s will to solve his disease! apple.news/ABm5Z620GS5W61…

10 resolutions for successful leaders to have in the new year businessinsider.com/skills-be-bett… via @businessinsider

Really delightful use of machine vision.

Importance of repeated stimulation of immune system with maintenance BCG has been known; forgotten; restudied; known again; forgotten; restudied again ... enough times that if someone says to you “I don’t believe in maintenance BCG” just show them the door out #GU20 #GU2020

Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing | Global Health | JAMA | JAMA Network - they only have 50 cases! jamanetwork.com/journals/jama/…

In Depth Assessment of Emerging Therapies for BCG Unresponsive NMIBC European Urology Oncology @UroToday Sam S. Chang MD, MBA Wes Kassouf Arjun Balar MD @BrantInman European Urology Bladder Cancer Advocacy Network MD Anderson Cancer Center #BladderCancer euoncology.europeanurology.com/article/S2588-…

Congratulations Rob well deserved!

We want to thank all the patients that participated in the trial and investigators of our Phase 3 trial!@BladderCancerUS Society of Urologic Oncology

Excited to share our advances in #bladdercancer research at Society of Urologic Oncology's #SUO2023! BOND-003's Phase 3 results presented by Mark Tyson of Mayo Clinic will cover our innovative #immunotherapy approaches targeting #BCG-unresponsive #NMIBC 📰 bit.ly/3QJhGiQ (Abstract #3396)

Breaking Paradigms: #Cretostimogene monotherapy #BOND-003 demonstrates significant durability & tolerability with no major AEs. FDA grants Fast Track & Breakthrough Therapy designation. Mark Tyson discusses on UroToday > bit.ly/4aZcGQ8 #BladderCancer CG Oncology, Inc.

#AUA24 join Armine Smith tomorrow AM for Optimizing Care for Women with #BladderCancer, a course offering up-to-date, evidence-based guidance on surgical mgmt of bladder cancer in women while preserving sexual function. 🗓️Sat, May 4 ⏰10-noon (CT) 📍212 aua2021.app.swapcard.com/event/2024-ann…

WATCH: Background, Methods, and Design of BOND-003 in #NMIBC With Mark Tyson | #AUA2024 targetedonc.com/view/backgroun…

Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CIS. #AUA2024 #NMIBC onclive.com/view/dr-tyson-…

We're thrilled to present our latest data today! Join us to hear from Rob Svatek, MD & Mark Tyson as they present on their respective ongoing trials: PIVOT-006 at 10:24 am and BOND-003 at 10:56 am CDT in the Learning Lab. Come join us! 👉Full agenda: auanet.org/AUA2024

It was a full house at the #AUA2024 "Clinical Trials in Progress, Bladder Cancer" session, featuring presentations by Rob Svatek on the PIVOT-006 study & Mark Tyson on the BOND-003- Cohort P. Learn more and discover our latest advances in #bladdercancer at booth #100! 🤝

In updated Phase 3 BOND-003 data shared at #SUO2024, cretostimogene grenadenorepvec showed sustained, durable complete responses in high-risk BCG-unresponsive #NMIBC. See how CG Oncology is advancing innovation in the fight against #bladdercancer.

Last week our team was honored to participate in the annual BCAN Bladder Cancer Think Tank Meeting in Washington D.C. Thank you to #BCAN for convening such an important and impactful forum.